Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245966879> ?p ?o ?g. }
- W4245966879 endingPage "e33" @default.
- W4245966879 startingPage "e21" @default.
- W4245966879 abstract "Background Non-steroidal anti-inflammatory drugs (NSAIDs) are the backbone of osteoarthritis pain management. We aimed to assess the effectiveness of different preparations and doses of NSAIDs on osteoarthritis pain in a network meta-analysis. Methods For this network meta-analysis, we considered randomised trials comparing any of the following interventions: NSAIDs, paracetamol, or placebo, for the treatment of osteoarthritis pain. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) and the reference lists of relevant articles for trials published between Jan 1, 1980, and Feb 24, 2015, with at least 100 patients per group. The prespecified primary and secondary outcomes were pain and physical function, and were extracted in duplicate for up to seven timepoints after the start of treatment. We used an extension of multivariable Bayesian random effects models for mixed multiple treatment comparisons with a random effect at the level of trials. For the primary analysis, a random walk of first order was used to account for multiple follow-up outcome data within a trial. Preparations that used different total daily dose were considered separately in the analysis. To assess a potential dose–response relation, we used preparation-specific covariates assuming linearity on log relative dose. Findings We identified 8973 manuscripts from our search, of which 76 randomised trials with a total of 58 451 patients were included in this analysis. 23 nodes concerning seven different NSAIDs or paracetamol with specific daily dose of administration or placebo were considered. All preparations, irrespective of dose, improved point estimates of pain symptoms when compared with placebo. For six interventions (diclofenac 150 mg/day, etoricoxib 30 mg/day, 60 mg/day, and 90 mg/day, and rofecoxib 25 mg/day and 50 mg/day), the probability that the difference to placebo is at or below a prespecified minimum clinically important effect for pain reduction (effect size [ES] −0·37) was at least 95%. Among maximally approved daily doses, diclofenac 150 mg/day (ES −0·57, 95% credibility interval [CrI] −0·69 to −0·45) and etoricoxib 60 mg/day (ES −0·58, −0·74 to −0·43) had the highest probability to be the best intervention, both with 100% probability to reach the minimum clinically important difference. Treatment effects increased as drug dose increased, but corresponding tests for a linear dose effect were significant only for naproxen (p=0·034). We found no evidence that treatment effects varied over the duration of treatment. Model fit was good, and between-trial heterogeneity and inconsistency were low in all analyses. All trials were deemed to have a low risk of bias for blinding of patients. Effect estimates did not change in sensitivity analyses with two additional statistical models and accounting for methodological quality criteria in meta-regression analysis. Interpretation On the basis of the available data, we see no role for single-agent paracetamol for the treatment of patients with osteoarthritis irrespective of dose. We provide sound evidence that diclofenac 150 mg/day is the most effective NSAID available at present, in terms of improving both pain and function. Nevertheless, in view of the safety profile of these drugs, physicians need to consider our results together with all known safety information when selecting the preparation and dose for individual patients. Funding Swiss National Science Foundation (grant number 405340-104762) and Arco Foundation, Switzerland. Non-steroidal anti-inflammatory drugs (NSAIDs) are the backbone of osteoarthritis pain management. We aimed to assess the effectiveness of different preparations and doses of NSAIDs on osteoarthritis pain in a network meta-analysis. For this network meta-analysis, we considered randomised trials comparing any of the following interventions: NSAIDs, paracetamol, or placebo, for the treatment of osteoarthritis pain. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) and the reference lists of relevant articles for trials published between Jan 1, 1980, and Feb 24, 2015, with at least 100 patients per group. The prespecified primary and secondary outcomes were pain and physical function, and were extracted in duplicate for up to seven timepoints after the start of treatment. We used an extension of multivariable Bayesian random effects models for mixed multiple treatment comparisons with a random effect at the level of trials. For the primary analysis, a random walk of first order was used to account for multiple follow-up outcome data within a trial. Preparations that used different total daily dose were considered separately in the analysis. To assess a potential dose–response relation, we used preparation-specific covariates assuming linearity on log relative dose. We identified 8973 manuscripts from our search, of which 76 randomised trials with a total of 58 451 patients were included in this analysis. 23 nodes concerning seven different NSAIDs or paracetamol with specific daily dose of administration or placebo were considered. All preparations, irrespective of dose, improved point estimates of pain symptoms when compared with placebo. For six interventions (diclofenac 150 mg/day, etoricoxib 30 mg/day, 60 mg/day, and 90 mg/day, and rofecoxib 25 mg/day and 50 mg/day), the probability that the difference to placebo is at or below a prespecified minimum clinically important effect for pain reduction (effect size [ES] −0·37) was at least 95%. Among maximally approved daily doses, diclofenac 150 mg/day (ES −0·57, 95% credibility interval [CrI] −0·69 to −0·45) and etoricoxib 60 mg/day (ES −0·58, −0·74 to −0·43) had the highest probability to be the best intervention, both with 100% probability to reach the minimum clinically important difference. Treatment effects increased as drug dose increased, but corresponding tests for a linear dose effect were significant only for naproxen (p=0·034). We found no evidence that treatment effects varied over the duration of treatment. Model fit was good, and between-trial heterogeneity and inconsistency were low in all analyses. All trials were deemed to have a low risk of bias for blinding of patients. Effect estimates did not change in sensitivity analyses with two additional statistical models and accounting for methodological quality criteria in meta-regression analysis. On the basis of the available data, we see no role for single-agent paracetamol for the treatment of patients with osteoarthritis irrespective of dose. We provide sound evidence that diclofenac 150 mg/day is the most effective NSAID available at present, in terms of improving both pain and function. Nevertheless, in view of the safety profile of these drugs, physicians need to consider our results together with all known safety information when selecting the preparation and dose for individual patients." @default.
- W4245966879 created "2022-05-12" @default.
- W4245966879 creator A5007871238 @default.
- W4245966879 creator A5025015753 @default.
- W4245966879 creator A5032983255 @default.
- W4245966879 creator A5038409870 @default.
- W4245966879 creator A5057426061 @default.
- W4245966879 creator A5069082766 @default.
- W4245966879 creator A5087638431 @default.
- W4245966879 date "2017-07-01" @default.
- W4245966879 modified "2023-10-11" @default.
- W4245966879 title "Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis" @default.
- W4245966879 cites W1538368282 @default.
- W4245966879 cites W1599185368 @default.
- W4245966879 cites W1938519604 @default.
- W4245966879 cites W1977849057 @default.
- W4245966879 cites W1988145586 @default.
- W4245966879 cites W2000715672 @default.
- W4245966879 cites W2004040899 @default.
- W4245966879 cites W2004210035 @default.
- W4245966879 cites W2010699829 @default.
- W4245966879 cites W2010818945 @default.
- W4245966879 cites W2013399300 @default.
- W4245966879 cites W2024588402 @default.
- W4245966879 cites W2030838816 @default.
- W4245966879 cites W2033451677 @default.
- W4245966879 cites W2035833931 @default.
- W4245966879 cites W2063738853 @default.
- W4245966879 cites W2067545718 @default.
- W4245966879 cites W2091808438 @default.
- W4245966879 cites W2096722523 @default.
- W4245966879 cites W2096883889 @default.
- W4245966879 cites W2099880429 @default.
- W4245966879 cites W2113144077 @default.
- W4245966879 cites W2127741681 @default.
- W4245966879 cites W2129281457 @default.
- W4245966879 cites W2139898754 @default.
- W4245966879 cites W2141783462 @default.
- W4245966879 cites W2144625636 @default.
- W4245966879 cites W2155336959 @default.
- W4245966879 cites W2161736885 @default.
- W4245966879 cites W2161739351 @default.
- W4245966879 cites W2164036238 @default.
- W4245966879 cites W2167439117 @default.
- W4245966879 cites W2170978402 @default.
- W4245966879 doi "https://doi.org/10.1016/s0140-6736(17)31744-0" @default.
- W4245966879 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28699595" @default.
- W4245966879 hasPublicationYear "2017" @default.
- W4245966879 type Work @default.
- W4245966879 citedByCount "324" @default.
- W4245966879 countsByYear W42459668792017 @default.
- W4245966879 countsByYear W42459668792018 @default.
- W4245966879 countsByYear W42459668792019 @default.
- W4245966879 countsByYear W42459668792020 @default.
- W4245966879 countsByYear W42459668792021 @default.
- W4245966879 countsByYear W42459668792022 @default.
- W4245966879 countsByYear W42459668792023 @default.
- W4245966879 crossrefType "journal-article" @default.
- W4245966879 hasAuthorship W4245966879A5007871238 @default.
- W4245966879 hasAuthorship W4245966879A5025015753 @default.
- W4245966879 hasAuthorship W4245966879A5032983255 @default.
- W4245966879 hasAuthorship W4245966879A5038409870 @default.
- W4245966879 hasAuthorship W4245966879A5057426061 @default.
- W4245966879 hasAuthorship W4245966879A5069082766 @default.
- W4245966879 hasAuthorship W4245966879A5087638431 @default.
- W4245966879 hasConcept C126322002 @default.
- W4245966879 hasConcept C142724271 @default.
- W4245966879 hasConcept C1862650 @default.
- W4245966879 hasConcept C204787440 @default.
- W4245966879 hasConcept C2776164576 @default.
- W4245966879 hasConcept C2778227786 @default.
- W4245966879 hasConcept C71924100 @default.
- W4245966879 hasConcept C95190672 @default.
- W4245966879 hasConceptScore W4245966879C126322002 @default.
- W4245966879 hasConceptScore W4245966879C142724271 @default.
- W4245966879 hasConceptScore W4245966879C1862650 @default.
- W4245966879 hasConceptScore W4245966879C204787440 @default.
- W4245966879 hasConceptScore W4245966879C2776164576 @default.
- W4245966879 hasConceptScore W4245966879C2778227786 @default.
- W4245966879 hasConceptScore W4245966879C71924100 @default.
- W4245966879 hasConceptScore W4245966879C95190672 @default.
- W4245966879 hasIssue "10090" @default.
- W4245966879 hasLocation W42459668791 @default.
- W4245966879 hasLocation W42459668792 @default.
- W4245966879 hasOpenAccess W4245966879 @default.
- W4245966879 hasPrimaryLocation W42459668791 @default.
- W4245966879 hasRelatedWork W1984915052 @default.
- W4245966879 hasRelatedWork W1998615235 @default.
- W4245966879 hasRelatedWork W2010845933 @default.
- W4245966879 hasRelatedWork W2050273324 @default.
- W4245966879 hasRelatedWork W2188489433 @default.
- W4245966879 hasRelatedWork W3147335770 @default.
- W4245966879 hasRelatedWork W3156300412 @default.
- W4245966879 hasRelatedWork W4213055852 @default.
- W4245966879 hasRelatedWork W4238952113 @default.
- W4245966879 hasRelatedWork W4283712195 @default.
- W4245966879 hasVolume "390" @default.
- W4245966879 isParatext "false" @default.